Radiation nanosensitizers in cancer therapy-From preclinical discoveries to the outcomes of early clinical trials.
Fiche publication
Date publication
janvier 2022
Journal
Bioengineering & translational medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MILLOT Nadine
Tous les auteurs :
Bilynsky C, Millot N, Papa AL
Lien Pubmed
Résumé
Improving the efficacy and spatial targeting of radiation therapy while sparing surrounding normal tissues has been a guiding principle for its use in cancer therapy. Nanotechnologies have shown considerable growth in terms of innovation and the development of new therapeutic approaches, particularly as radiosensitizers. The aim of this study was to systematically review how nanoparticles (NPs) are used to enhance the radiotherapeutic effect, including preclinical and clinical studies. Clinicaltrials.gov was used to perform the search using the following terms: radiation, cancer, and NPs. In this review, we describe the various designs of nano-radioenhancers, the rationale for using such technology, as well as their chemical and biological effects. Human trials are then discussed with an emphasis on their design and detailed clinical outcomes.
Mots clés
cancer, nanosized radiosensitizers, radiotherapy
Référence
Bioeng Transl Med. 2022 Jan;7(1):e10256